Baxter International Inc.
NYSE:BAXMedical - Instruments & Supplies
-$1.07 today
- Market cap
- $13.53B
- Beta
- 0.64
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.13
- Dividend yield
- 1.03%
Volume 4.01M
Average 7.62M
BAX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Baxter International Inc.NYSE: BAX
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $239M fell 7.0% year over year, behind the -5.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at -2.9% a year.
Context
- Depreciation & amortization amounted to 8.7% of revenue in FY2025, down 0.6 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -7.0% toward the trailing-twelve-month pace of -5.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 981M USD
- Year-over-year change
- -1.6%
- 4-year CAGR
- +3.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 981M | -1.6% |
| FY2024 | 2024-12-31 | 997M | +1.3% |
| FY2023 | 2023-12-31 | 984M | -8.2% |
| FY2022 | 2022-12-31 | 1.07B | +23.6% |
| FY2021 | 2021-12-31 | 867M | — |
Depreciation & Amortization vs competitors
How BAX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.0% is the lowest of 5, against a peer median of -0.9%.
- Depreciation & amortization amounts to 8.3% of revenue for BAX, versus a peer median of 8.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €1.56B EUR | -3.5% | -6.5% | 8.0% | |
| LTM Jun 2026 | $953M USD | -5.0% | -2.9% | 8.3% | |
| LTM Jun 2026 | $709.83M USD | -0.3% | -0.8% | 5.1% | |
| LTM Jun 2026 | $204.78M USD | -1.5% | -5.1% | 9.5% | |
| LTM Mar 2026 | $13.25M USD | +2.4% | -0.2% | 9.3% | |
| Peer median (excluding BAX) | — | -0.9% | -3.0% | 8.7% | |
Competitors are the stored peer set for BAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.03B | (3.11B) | 181M | (326M) | (957M) |
| Depreciation & Amortization | 867M | 1.07B | 984M | 997M | 981M |
| Deferred Income Tax | (161M) | (260M) | (256M) | (262M) | 77M |
| Stock-Based Compensation | 146M | 140M | 115M | 114M | 117M |
| Change in Working Capital | (57M) | (606M) | 161M | (236M) | (108M) |
| Accounts Receivables | (170M) | (48M) | (38M) | (35M) | (132M) |
| Inventory | (27M) | (198M) | (128M) | (201M) | (119M) |
| Accounts Payables | 105M | (67M) | 92M | 112M | 3M |
| Other Working Capital | 35M | (293M) | 235M | (112M) | 140M |
| Other Non-Cash Items | 394M | 3.98B | 541M | 732M | 735M |
| Operating Cash Flow | 2.22B | 1.21B | 1.73B | 1.02B | 845M |
| Capital Expenditures | (691M) | (635M) | (436M) | (460M) | (522M) |
| Acquisitions (Net) | (10.5B) | (263M) | (6M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 34M | 0 |
| Other Investing Activities | (7M) | (33M) | 3.66B | (200M) | 3.35B |
| Investing Cash Flow | (11.2B) | (931M) | 3.21B | (626M) | 2.84B |
| Debt Repayment | 9.33B | (899M) | (2.94B) | (531M) | (3.79B) |
| Common Stock Issued | 187M | 127M | 95M | 71M | 30M |
| Common Stock Repurchased | (600M) | (32M) | 0 | 0 | 0 |
| Dividends Paid | (530M) | (573M) | (586M) | (590M) | (348M) |
| Other Financing Activities | (138M) | (61M) | (63M) | (31M) | (107M) |
| Financing Cash Flow | 8.25B | (1.44B) | (3.49B) | (1.08B) | (4.22B) |
| Effect of Forex Changes | (47M) | (76M) | 26M | (96M) | 84M |
| Net Change in Cash | (780M) | (1.23B) | 1.48B | (784M) | (446M) |
| Free Cash Flow | 1.53B | 576M | 1.29B | 559M | 323M |
Baxter International Inc.
NYSE:BAX
Intrinsic Alpha fair value
Locked
Current Price
$26.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.